LENZ Therapeutics, Inc.
$10.13
▲
3.42%
2026-04-21 07:51:01
www.lenz-tx.com
NMS: LENZ
Explore LENZ Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$319.19 M
Current Price
$10.13
52W High / Low
$50.4 / $8.25
Stock P/E
—
Book Value
$9.07
Dividend Yield
—
ROCE
-32.01%
ROE
-33.63%
Face Value
—
EPS
$-2.85
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
152
Beta
2.29
Debt / Equity
0.29
Current Ratio
14.23
Quick Ratio
14.09
Forward P/E
-3.44
Price / Sales
14.9
Enterprise Value
$-7.15 M
EV / EBITDA
0.08
EV / Revenue
-0.37
Rating
Strong Buy
Target Price
$41.14
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aktis Oncology, Inc. | $20.83 | — | $1.08 B | — | -31.96% | -29.45% | $29.16 / $14.72 | $-159.68 |
| 2. | Cytokinetics, Incorporated | $65.05 | — | $8.11 B | — | -50.1% | 197.47% | $70.98 / $29.31 | $-5.37 |
| 3. | Coherus Oncology, Inc. | $1.99 | 1.76 | $295.28 M | — | -155.52% | -473.47% | $2.62 / $0.71 | $0.5 |
| 4. | Lisata Therapeutics, Inc. | $2.83 | — | $25.56 M | — | -124.1% | -75.53% | $5.07 / $1.81 | $1.68 |
| 5. | 60 Degrees Pharmaceuticals, Inc. | $1.84 | — | $4.69 M | — | -220.2% | -2.01% | $17.68 / $1.29 | $-5.25 |
| 6. | Climb Bio, Inc. | $8.97 | — | $437.55 M | — | -42.23% | -32.15% | $9.4 / $1.13 | $3.36 |
| 7. | Turn Therapeutics Inc. | $3.38 | — | $103.07 M | — | -134.02% | -1.42% | $26.5 / $2.57 | $0.02 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.59 M | 12.5 M | 5 M | 0 M | 0 M | — |
| Operating Profit | -38.46 M | -18.89 M | -16.86 M | -16.93 M | -15.22 M | — |
| Net Profit | -35.9 M | -16.7 M | -14.91 M | -14.62 M | -12.65 M | — |
| EPS in Rs | -1.14 | -0.53 | -0.48 | -0.47 | -0.4 | -0.38 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 19.09 M | 0 M | 0 M | 15 M |
| Operating Profit | -91.14 M | -58.61 M | -72.43 M | -10.48 M |
| Net Profit | -82.13 M | -49.77 M | -69.97 M | -10.81 M |
| EPS in Rs | -2.62 | -1.59 | -2.23 | -0.34 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 305.88 M | 215.3 M | 70.38 M | 46.95 M |
| Total Liabilities | 21.54 M | 11.22 M | 163.09 M | 71.12 M |
| Equity | 284.34 M | 204.08 M | -92.71 M | -24.17 M |
| Current Assets | 301.41 M | 211.92 M | 67.24 M | 46.64 M |
| Current Liabilities | 21.19 M | 10.41 M | 18.51 M | 9.5 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -69.17 M | -59.39 M | -60.38 M | -4.09 M |
| Investing CF | -75.67 M | -154.48 M | -29.62 M | -0.04 M |
| Financing CF | 149.75 M | 199 M | 80.7 M | 30.26 M |
| Free CF | -70 M | -59.86 M | -60.41 M | -4.13 M |
| Capex | -0.83 M | -0.47 M | -0.03 M | -0.04 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | -100% | — |
| Earnings Growth % | -65.02% | 28.87% | -547.19% | — |
| Profit Margin % | -430.25% | — | — | -72.07% |
| Operating Margin % | -477.46% | — | — | -69.89% |
| Gross Margin % | 97.81% | — | — | — |
| EBITDA Margin % | -475.96% | — | — | -69.83% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2024-03-22 | $7.21 |
| 2024-03-15 | $7.21 |
Stock Splits
| Date | Split |
|---|---|
| 2024-03-22 | 1:0.142857 |